GENTAMICIN POPULATION PHARMACOKINETICS IN INDIAN PEDIATRIC PATIENTS
Abstract
Objective: The objective of this study was to characterize gentamicin population pharmacokinetics (PKs) in Indian pediatric patients.
Methods: Population PK analysis was performed with nonlinear mixed-effect model software. The data set was inspected using both first order (FO)
and FO conditional estimate (FOCE) methods by the inclusion of both patient and pathological conditions.
Results: A total of 26 patients were involved in this study with 54 observations. The patient covariates, including body weight, gender, age, and
creatinine clearance (CLCR), were analyzed in a stepwise fashion to identify their potential influences on gentamicin PKs. The final model
gives the clearance (CL) and volume of distribution (V) by FO method as CL=θ1*(CLCR/35.14)+θ3*(WT/14.25)+θ5*(AGE/6.14)*EXP(θ1),
V=θ2*(WT/14.25)+θ4*(CLCR/35.14)+θ6*(AGE/6.14)*EXP(θ2) and by FOCE method as CL=θ1*(CLCR/35.14+)θ3*(AGE/6.14)*EXP(θ1),
V=θ2*(WT/14.25)+θ4*(CLCR/35.14)+θ6*(AGE/6.14)*EXP(θ2).
Conclusion: The final model estimates of CL and V were 0.0014 L/hr/kg and 0.646 L/kg, respectively, and by FOCE method were 0.0014E-06 L/hr/kg
and 0.774 L/kg, respectively. These parameters will be helpful in individualizing the loading and maintenance doses in pediatric patients.
Keywords: Population pharmacokinetics, Gentamicin, Nonlinear mixed-effect model, Pediatrics.
Downloads
References
REFERENCES
Hansen M, Christrup LL, Jarløv JO, Kampmann JP, Bonde J.
Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand
;45(2):734-40.
Avent ML, Kinney JS, Istre GR, Whitfield JM. Gentamicin and
tobramycin in neonates: Comparison of a new extended dosing
interval regimen with a traditional multiple daily dosing regimen. Am J
Perinatol 2002;19(8):413-20.
Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW,
Quintiliani R. Experience with a once-daily aminoglycoside program
administered to 2,184 adult patients. Antimicrob Agents Chemother
;39(3):650-5.
van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA.
Impact of goal-oriented and model-based clinical pharmacokinetic
dosing of aminoglycosides on clinical outcome: A cost-effectiveness
analysis. Ther Drug Monit 1999;21(1):63-73.
Chattopadhyay B. Newborns and gentamicin – how much and how
often? J Antimicrob Chemother 2002;49(1):13-6.
van Maarseveen E, Man WH, Proost J, Neef C, Touw D.
Chronopharmacokinetics of once daily dosed aminoglycosides in
hospitalized infectious patients. Int J Clin Pharm 2015;37(2):342-7.
Mercado MC, Brodsky NL, McGuire MK, Hurt H. Extended interval
dosing of gentamicin in preterm infants. Am J Perinatol 2004;21(2):73-7.
Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ,
Darlow BA. An extended interval dosing method for gentamicin in
neonates. J Antimicrob Chemother 2001;48(6):887-93.
Asian J Pharm Clin Res, Vol 9, Issue 3, 2016, 311-315
Goda et al.
Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval
gentamicin: Population pharmacokinetics in pediatric critical illness.
Pediatr Crit Care Med 2010;11(2):267-74.
Bakri FE, Pallett A, Smith AG, Duncombe AS. Once-daily versus
multiple-daily gentamicin in empirical antibiotic therapy of febrile
neutropenia following intensive chemotherapy. J Antimicrob
Chemother 2000;45(3):383-6.
Newby B, Prevost D, Lotocka-Reysner H. Assessment of gentamicin
mg/kg once daily for pediatric patients with febrile neutropenia: A
pilot project. J Oncol Pharm Pract 2009;15(4):211-6.
Nielsen EI, Sandström M, Honoré PH, Ewald U, Friberg LE.
Developmental pharmacokinetics of gentamicin in preterm and
term neonates: Population modelling of a prospective study. Clin
Pharmacokinet 2009;48(4):253-63.
Dersch-Mills D, Akierman A, Alshaikh B, Sundaram A, Yusuf K.
Performance of a dosage individualization table for extended interval
gentamicin in neonates beyond the first week of life. J Matern Fetal
Neonatal Med 2015;29(9):1-6.
Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal
aminoglycoside dosing in critically ill patients. Ther Drug Monit
;30(6):674-81.
Botha JH, du Preez MJ, Adhikari M. Population pharmacokinetics
of gentamicin in South African newborns. Eur J Clin Pharmacol
;59(10):755-9.
Thomson AH, Kokwaro GO, Muchohi SN, English M, Mohammed S,
Edwards G. Population pharmacokinetics of intramuscular gentamicin
administered to young infants with suspected severe sepsis in Kenya.
Br J Clin Pharmacol 2003;56(1):25-31.
Matthews I, Kirkpatrick C, Holford N. Quantitative justification
for target concentration intervention – parameter variability and
predictive performance using population pharmacokinetic models for
aminoglycosides. Br J Clin Pharmacol 2004;58(1):8-19.
Aarons L. Population pharmacokinetics: Theory and practice. Br J Clin
Pharmacol 1991;32(6):669-70.
Sheiner LB, Beal SL. Evaluation of methods for estimating population
pharmacokinetic parameters. II. Biexponential model and experimental
pharmacokinetic data. J Pharmacokinet Biopharm 1981;9(5):635-51.
Sheiner LB, Beal SL. Evaluation of methods for estimating
population pharmacokinetic parameters. III. Monoexponential model:
Routine clinical pharmacokinetic data. J Pharmacokinet Biopharm
;11(3):303-19.
Bartels H. Serum creatinine and creatinine clearance. Med Welt
;23(27):961-3.
Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics
of gentamicin in neonates using a nonlinear, mixed-effects model.
Pharmacotherapy 1992;12(3):178-82.
Frymoyer A, Meng L, Bonifacio SL, Verotta D, Guglielmo BJ.
Gentamicin pharmacokinetics and dosing in neonates with hypoxic
ischemic encephalopathy receiving hypothermia. Pharmacotherapy
;33(7):718-26.
Rosario MC, Thomson AH, Jodrell DI, Sharp CA, Elliott HL.
Population pharmacokinetics of gentamicin in patients with cancer. Br
J Clin Pharmacol 1998;46(3):229-36.
Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of
gentamicin in hospitalized patients receiving once-daily dosing. Int J
Antimicrob Agents 2004;23(3):291-5.
Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin
pharmacokinetics in neonates. Br J Clin Pharmacol 2005;59(1):54-61.
GarcÃa B, Barcia E, Pérez F, Molina IT. Population pharmacokinetics
of gentamicin in premature newborns. J Antimicrob Chemother
;58(2):372-9.
Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, et al.
Population pharmacokinetic study of gentamicin in a large cohort of
premature and term neonates. Br J Clin Pharmacol 2014;78(5):1090-101.
MedellÃn-Garibay SE, Rueda-Naharro A, Peña-Cabia S, GarcÃa B,
Romano-Moreno S, Barcia E. Population pharmacokinetics of
gentamicin and dosing optimization for infants. Antimicrob Agents
Chemother 2015;59(1):482-9.
Fattinger K, Vozeh S, Olafsson A, Vlcek J, Wenk M, Follath F.
Netilmicin in the neonate: Population pharmacokinetic analysis and
dosing recommendations. Clin Pharmacol Ther 1991;50(1):55-65.
Ho KK, Bryson SM, Thiessen JJ, Greenberg ML, Einarson TR,
Leson CL. The effects of age and chemotherapy on gentamicin
pharmacokinetics and dosing in pediatric oncology patients.
Pharmacotherapy 1995;15(6):754-64.
Postovsky S, Ben Arush MW, Kassis E, Elhasid R, Krivoy N.
Pharmacokinetic analysis of gentamicin thrice and single daily dosage
in pediatric cancer patients. Pediatr Hematol Oncol 1997;14(6):547-54.
Bass KD, Larkin SE, Paap C, Haase GM. Pharmacokinetics of
once-daily gentamicin dosing in pediatric patients. J Pediatr Surg
;33(7):1104-7.
Uijtendaal EV, Rademaker CM, Schobben AF, Fleer A, Kramer WL,
van Vught AJ, et al. Once-daily versus multiple-daily gentamicin in
infants and children. Ther Drug Monit 2001;23(5):506-13.
Sherwin CM, Kostan E, Broadbent RS, Medlicott NJ, Reith DM.
Evaluation of the effect of intravenous volume expanders upon the
volume of distribution of gentamicin in septic neonates. Biopharm
Drug Dispos 2009;30(5):276-80.
Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3 mg/kg
body weight loading dose of gentamicin or tobramycin in critically ill
patients. Chest 1989;95(6):1295-7.
Triginer C, Izquierdo I, Fernández R, Rello J, Torrent J, Benito S,
et al. Gentamicin volume of distribution in critically ill septic patients.
Intensive Care Med 1990;16(5):303-6.
Dorman T, Swoboda S, Zarfeshenfard F, Trentler B, Lipsett PA. Impact
of altered aminoglycoside volume of distribution on the adequacy of
a three milligram per kilogram loading dose. Critical care Research
Group. Surgery 1998;124(1):73-8.
Oparaoji EC, Siram S, Shoheiber O, Cornwell EE 3
, Mezghebe
HM. Appropriateness of a 4 mg/kg gentamicin or tobramycin loading
dose in post-operative septic shock patients. J Clin Pharm Ther
;23(3):185-90.
Tang GJ, Tang JJ, Lin BS, Kong CW, Lee TY. Factors affecting
gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol
Scand 1999;43(7):726-30.
De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and
pharmacodynamic considerations when treating patients with sepsis
and septic shock. Clin Pharmacokinet 2002;41(14):1135-51.
Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple
estimate of glomerular filtration rate in children derived from body
length and plasma creatinine. Pediatrics 1976;58(2):259-63.
Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of
aminoglycosides in neonates. Clin Pharmacokinet 2009;48(2):71-88.
Marsot A, Boulamery A, Bruguerolle B, Simon N. Population
pharmacokinetic analysis during the first 2 years of life: An overview.
Clin Pharmacokinet 2012;51(12):787-98.
Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L.
Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol
;44 Suppl 1:S23-5.
Sampson MR, Frymoyer A, Rattray B, Cotten CM, Smith PB,
Capparelli E, et al. Predictive performance of a gentamicin population
pharmacokinetic model in neonates receiving full-body hypothermia.
Ther Drug Monit 2014;36(5):584-9.
rd
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.